ERBB2 and colorectal cancer: Conflicting data exist about the prevalence of HER-2/neu overexpression in colorectal cancer, which ranges from 0 to 83 % [12-16] as well as the relationship between HER-2/neu overexpression and clinicopathologic features like Dukes classification and survival.